Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Accounts Payables: 2013-2025

Historic Accounts Payables for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $24.9 million.

  • Coherus Oncology's Accounts Payables rose 13.70% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 13.70%. This contributed to the annual value of $28.5 million for FY2024, which is 19.20% down from last year.
  • Latest data reveals that Coherus Oncology reported Accounts Payables of $24.9 million as of Q3 2025, which was down 33.83% from $37.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Accounts Payables registered a high of $76.8 million during Q2 2024, and its lowest value of $9.9 million during Q3 2022.
  • For the 3-year period, Coherus Oncology's Accounts Payables averaged around $35.8 million, with its median value being $35.2 million (2023).
  • As far as peak fluctuations go, Coherus Oncology's Accounts Payables skyrocketed by 281.21% in 2021, and later plummeted by 78.30% in 2022.
  • Coherus Oncology's Accounts Payables (Quarterly) stood at $16.2 million in 2021, then dropped by 28.67% to $11.5 million in 2022, then skyrocketed by 205.56% to $35.2 million in 2023, then declined by 19.20% to $28.5 million in 2024, then increased by 13.70% to $24.9 million in 2025.
  • Its Accounts Payables was $24.9 million in Q3 2025, compared to $37.6 million in Q2 2025 and $40.9 million in Q1 2025.